|Bid||31.22 x 1000|
|Ask||31.23 x 2200|
|Day's range||30.75 - 31.52|
|52-week range||28.00 - 37.61|
|Beta (3Y monthly)||N/A|
|PE ratio (TTM)||112.72|
|Earnings date||30 Apr 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||34.27|
How Major Pharmaceutical Stocks Are Positioned This Month(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts have set Eli Lilly and Company’s (LLY) 12-month consensus target price at $122, 2.59% lower than
Elanco Animal Health Incorporated (ELAN) today announced the appointment of four new members to the Board of Directors. The Board was initially established in September 2018 when Elanco became a publicly traded company following its separation from Eli Lilly and Company. The appointments follow Lilly’s full divestiture of Elanco, making Elanco a fully independent company.
Why Eli Lilly Stock Fell YesterdayStock price movements Yesterday, Eli Lilly (LLY) closed at $123.50, 2.53% lower than its previous closing price, 65.75% higher than its 52-week low of $74.51, and 5.37% below its 52-week high of $130.51. The
Elanco Animal Health Incorporated (ELAN) today announced that it is now a fully independent company. The completion of Eli Lilly and Company’s exchange offer completes the journey Elanco began in 2017 when its former parent company first announced the exploration of potential strategic alternatives for the 64-year-old animal health company. The exchange offer was 7.6x oversubscribed.
Elanco or Zoetis: Which Is a Better Animal Health Pick in February?(Continued from Prior Part)Revenue guidance for fiscal 2019In its fourth-quarter earnings investor presentation, Elanco Animal Health (ELAN) confirmed its fiscal 2019 guidance
Elanco or Zoetis: Which Is a Better Animal Health Pick in February?Stock price movementsOn February 19, Elanco Animal Health (ELAN) closed at $29.16, 1.49% lower than its previous closing price, 4.14% higher than its 52-week low of $28.00, and
Investors need to pay close attention to Elanco Health (ELAN) stock based on the movements in the options market lately.
The drug giant announced on Friday that it will unload the remaining shares it holds of Elanco Animal Health through a voluntary stock-exchange offer.
Elanco Animal Health Incorporated (ELAN), formerly the animal health business of Eli Lilly and Company (Lilly), today announced it intends to file a Form S-4 Registration Statement with the Securities and Exchange Commission (SEC) in connection with Lilly’s proposed exchange offer whereby Lilly shareholders can exchange shares of Lilly common stock for shares of Elanco common stock owned by Lilly. The exchange offer is anticipated to be tax-free for participating Lilly shareholders in the United States, except with respect to cash received in lieu of fractional shares.
Full year global revenue increased 6 percent to $3.1 billion, Interceptor® Plus reaches blockbuster status with more than $100 million in annual sales
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead the company to an earnings beat.
Elanco Animal Health (ELAN) has revised the date for its fourth-quarter and full-year 2018 financial results announcement. Elanco will also conduct a conference call with the investment community and media on that day to further detail the company's financial performance. Elanco (ELAN) is a global animal health company that develops products and knowledge services to prevent and treat disease in food animals and pets in more than 90 countries.
Performance Livestock Analytics, Inc. and Elanco Animal Health Incorporated , today announce an agreement to provide joint customers data from PLA’s fast-growing Performance Beef TM platform and access to Elanco’s Benchmark ® service.
The Zacks Analyst Blog Highlights: Intuitive Surgical, Illumina, HCA, Elanco Animal and Humana
Earnings per share (EPS) for 2019 are expected to be in the range of $0.36 to $0.48 on a reported basis and $1.02 to $1.12 on an adjusted basis. The company now expects 2018 EPS to be in the range of $0.15 to $0.17 on a reported basis. On an adjusted basis, the company reaffirms its expectation for 2018 EPS to be in the range of $1.14 to $1.16.
Elanco Animal Health Incorporated (ELAN) will announce its financial guidance for 2019 on Tuesday, Dec. 18, 2018. Elanco will also conduct a conference call that day with the investment community to further detail the company's financial guidance. The conference call will begin at 8:00 a.m. Eastern time.
Elanco Animal Health Incorporated (ELAN) and Farm Radio International (FRI) have partnered to produce a 13-week series of radio programs designed to support and educate small-scale livestock farmers in North Tanzania to manage the challenges around livestock health and wellbeing, supporting a drive to greater food security, livestock health and care in the region. FRI and Elanco are working closely with local radio stations - Sauti ya Injili and Loliondo FM - to produce a short series of interactive radio programs, enabling listeners to make informed decisions, and have access to relevant animal health care products and training.
NEW YORK, Nov. 20, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Mallinckrodt soared early Tuesday after the pharma stock outperformed quarterly views, though Eli Lilly was more muted on its mixed report.
GREENFIELD, Ind.-- -- Third quarter revenue grew 9 percent to $761.1 million. Revenue, excluding strategic exits, grew 13 percent to $733.4 million; removing the impact of foreign currency exchange rates, growth was 15 percent. Reported net income grew $80.9 million in the third quarter to $60.2 million, which represents $0.16 per diluted share and $0.29 per diluted share on an adjusted basis. Delivered ...
The collaboration furthers Elanco’s commitment to antibiotic stewardship and offering alternatives to unmet needs. Elanco Animal Health Incorporated (ELAN), announced today a new global R&D collaboration with Novozymes A/S (OMX:NZYM B), the world leader in biological solutions, to develop nutritional health products for beef cattle and dairy cows globally. The effort will leverage Novozymes’ leading discovery and development programs, and together the companies will collaborate to develop a R&D pipeline and commercialize products in the next decade.